title: Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis.
abstract: OBJECTIVE
  To evaluate the psychometric properties of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and Visual Function Questionnaire Utility Index (VFQ-UI) in patients with non-infectious intermediate and posterior uveitis.
  
  
  METHODS
  Secondary analysis of pooled data from a 26-week, multicenter, masked, randomized, sham-controlled Phase 3 clinical trial. Health-related quality of life was assessed using the NEI VFQ-25, the EQ-5D, and SF-36. Internal consistency reliability, reproducibility, convergent validity, and known groups of BCVA and vitreous haze severity were assessed. Clinically significant difference was assessed using anchor-based and distribution-based methods.
  
  
  RESULTS
  The study included 224 subjects with non-infectious intermediate (80.4 %) or posterior uveitis (19.6 %). The NEI VFQ-25 and the VFQ-UI demonstrated good internal consistency (Cronbach's alpha 0.87-0.94) and test-retest reliability (ICCs 0.58-0.88). Spearman's product-moment rank correlations between the NEI VFQ-25 and VFQ-UI scores and the SF-6D, EQ-5D, and BCVA ranged from small to moderate. There was a significant association between visual functioning and known groups of visual acuity (p < 0.05). Clinical significance, using the anchor-based method (difference between visual acuity groups ≥10-<15 letter better and no change), was 10.2 for change from baseline to week 26 for the NEI VFQ-25 composite score and 0.05 for the VFQ-UI. Using the distribution-based method, the clinical significance was 3.86 for the composite score and 0.04 for the VFQ-UI.
  
  
  CONCLUSIONS
  The NEI VFQ-25 and the VFQ-UI are reliable and valid measures of vision-related functioning and preference-based status in patients with non-infectious intermediate and posterior uveitis.
authors: Global Health Outcomes Strategy and Research, Allergan Inc., 2525 Dupont Drive, Irvine, CA, 92612, USA.
authors: Rupali K
authors: RK
authors: Naik
authors: Katharine S
authors: KS
authors: Gries
authors: Anne M
authors: AM
authors: Rentz
authors: Jonathan W
authors: JW
authors: Kowalski
authors: Dennis A
authors: DA
authors: Revicki
mesh_terms: D000293:Adolescent; D005260:Female; D006304:Health Status; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D054554:National Eye Institute (U.S.); D063868:Patient Outcome Assessment; D011594:Psychometrics / Q000379:methods*; D011788:Quality of Life; D015203:Reproducibility of Results; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires / Q000592:standards*; D014481:United States; D014605:Uveitis / Q000503:physiopathology*; D014792:Visual Acuity
references: J Clin Epidemiol. 2008 Feb;61(2):102-9
references: 18177782
references: Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1169-76
references: 22247489
references: Arch Ophthalmol. 2001 Jul;119(7):1050-8
references: 11448327
references: Med Care. 1989 Mar;27(3 Suppl):S178-89
references: 2646488
references: Med Care. 2007 Dec;45(12):1162-70
references: 18007166
references: Ophthalmology. 2004 May;111(5):946-53
references: 15121373
references: Am J Ophthalmol. 2012 Jun;153(6):1025-30.e1
references: 22321801
references: J Health Econ. 2002 Mar;21(2):271-92
references: 11939242
references: Ophthalmologica. 2004 Jul-Aug;218(4):223-36
references: 15258410
references: Health Qual Life Outcomes. 2003 Apr 11;1:4
references: 12737635
references: Med Care. 1990 Jul;28(7):632-42
references: 2366602
references: Am J Ophthalmol. 1982 Jul;94(1):91-6
references: 7091289
references: Arch Ophthalmol. 2001 Jun;119(6):841-9
references: 11405835
references: Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
references: 15019324
references: Mayo Clin Proc. 2002 Apr;77(4):371-83
references: 11936935
references: Arch Ophthalmol. 2011 May;129(5):545-53
references: 21220619